

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[About Our Cancer Immunotherapy Program](#)
[Learn About Cancer & Treatment](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA

[Robins H, Merghoub T, Yuan J, Jungbluth A, Blando J, Sharma P, Rudensky AY, Wolchok JD, Allison JP. \(2018\) Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol Res. 6:189-200.](#)

[Green JA, Arpaia N, Schizas M, Dobrin A, Rudensky AY. \(2017\) A nonimmune function of T cells in promoting lung tumor progression. J Exp Med. 214:3565-3575.](#)

[Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV, Chudakov DM, Rudensky AY. \(2016\) Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. Immunity. 45:1122-1134.](#)

[Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbe C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine 2017;377:1345-56.](#)

[View more publications from Dr. Rudensky.](#)

[View more publications from Dr. Wolchok.](#)

Immune Monitoring

[Huang, A.C., M.A. Postow, R.J. Orlowski, R. Mick, B. Bengsch, S. Manne, W. Xu, S. Harmon, J.R. Giles, B. Wenz, M. Adamow, D. Kuk, K.S. Panageas, C. Carrera, P. Wong, F. Quagliarello, B. Wubbenhorst, K. D'Andrea, K.E. Pauken, R.S. Herati, R.P. Staupe, J.M. Schenkel, S. McGettigan, S. Kothari, S.M. George, R.H. Vonderheide, R.K. Amaravadi, G.C. Karakousis, L.M. Schuchter, X. Xu, K.L. Nathanson, J.D. Wolchok, T.C. Gangadhar, E.J. Wherry. \(2017\). T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545: 60-65.](#)

[Postow, M.A., M. Manuel, P. Wong, J. Yuan, Z. Dong, C. Liu, S. Perez, I. Tanneau, M. Noel, A. Courtier, N. Pasqual, J.D. Wolchok. \(2015\). Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. Journal for ImmunoTherapy of Cancer 3: 23.](#)

[Rizvi, N.A., M.D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J.J. Havel, W. Lee, J. Yuan, P. Wong, T.S. Ho, M.L. Miller, N. Rekhtman, A.L. Moreira, F. Ibrahim, C. Bruggeman, B. Gasmi, R. Zappasodi, Y. Maeda, C. Sander, E.B. Garon, T. Merghoub, J.D. Wolchok, T.N. Schumacher, T.A. Chan. \(2015\). Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124-128.](#)

[Snyder, A., V. Makarov, T. Merghoub, J. Yuan, J.M. Zaretsky, A. Desrichard, L.A. Walsh, M.A. Postow, P. Wong, T.S. Ho, T.J. Hollmann, C. Bruggeman, K. Kannan, Y. Li, C. Elipenahli, C. Liu, C.T. Harbison, L. Wang, A. Ribas, J.D. Wolchok, and T.A. Chan. \(2014\). Genetic basis for clinical response to CTLA-4 blockade in melanoma. *The New England Journal of Medicine* 371: 2189-99.](#)

[Kitano, S., M.A. Postow, C.G. Ziegler, D. Kuk, K.S. Panageas, C. Cortez, T. Rasalan, M. Adamow, J. Yuan, P. Wong, G. Altan-Bonnet, J.D. Wolchok, A.M. Lesokhin. \(2014\). Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. *Cancer Immunology Research* 2: 812-821.](#)

Publications supported by the Ludwig Center at MSK Basic and Translational Immunology Grants

2018

[Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, Nainys J, Wu K, Kisieliovas V, Setty M, Choi K, Fromme RM, Dao P, McKenney PT, Wasti RC, Kadaveru K, Mazutis L, Rudensky AY, Pe'er D. \(2018\) Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. *Cell*. S0092-8674:30723-2.](#)

2017

[Snyder A, Nathanson T, Funt SA, Ahuja A, Buros Novik J, Hellmann MD, Chang E, Aksoy BA, Al-Ahmadie H, Yusko E, Vignali M, Benzeno S, Boyd M, Moran M, Iyer G, Robins HS, Mardis ER, Merghoub T, Hammerbacher J, Rosenberg JE, Bajorin DF. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. \(2017\) *PLoS Med*. 14\(5\):e1002309.](#)

[Mass E, Jacome-Galarza CE, Blank T, Lazarov T, Durham BH, Ozkaya N, Pastore A, Schwabenland M, Chung YR, Rosenblum MK, Prinz M, Abdel-Wahab O, Geissmann F. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. \(2017\) *Nature* 549\(7672\):389-393.](#)

[Weizman O, Adams NM, Schuster I, Krishna C, Pritykin Y, Lau C, Degli-Esposti MA, Leslie CS, *Sun JC, *O'Sullivan TE. 2017. ILC1 confer early host protection at initial sites of viral infection. *Cell*. 171:795-808. *Corresponding Author.](#)

[*Rapp ME, *Lau CM, *Adams NM, Weizman O, O'Sullivan TE, Geary CD, Sun JC. 2017. Core-binding factor \$\beta\$ and Runx transcription factors promote adaptive natural killer cell responses. *Science Immunology*. 2\(18\):eaan3796. *These authors contributed equally to this work.](#)

[Chen, C.C., Kass, E.M., Yen, W.F., Ludwig, T., Moynahan, M.E., Chaudhuri, J., and Jasin, M. \(2017\) ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair *Proc Natl Acad Sci U S A*, 14:7665-7670.](#)

[O'Sullivan TE, Rapp ME, Fan X, Weizman O, Bhardwaj P, Adams NM, Walzer T, Dannenberg AJ, Sun JC. \(2016\) Adipose-resident group 1 innate lymphoid cells promote obesity-associated insulin resistance. *Immunity*. 45:428-441.](#)

[O'Sullivan TE, Geary CD, Weizman O, Geiger TL, Rapp ME, Dorn GW, Overholtzer M, Sun JC. \(2016\) Atg5 is essential for the development and survival of innate lymphocytes. *Cell Reports*. 15:1910-1919.](#)

[Adams NM, O'Sullivan TE, Geary CD, Karo JM, Amezcua RA, Joshi NS, Kaech SM, Sun JC. \(2016\) Natural Killer Cell Responses Redefine Immunological Memory. *J Immunol*. 197:2963-70.](#)

[Vaidyanathan B, Chaudhry A, Yewdell WT, Angeletti D, Yen WF, Wheatley AK, Bradfield CA, McDermott AB, Yewdell JW, Rudensky AY, Chaudhuri J. \(2017\) The aryl hydrocarbon receptor controls cell-fate decisions in B cells. *J Exp Med*. 214:197-208.](#)

[Yen WF, Chaudhry A, Vaidyanathan B, Yewdell WT, Pucella JN, Sharma R, Liang Y, Li K, Rudensky AY, Chaudhuri J. BRCT-domain protein BRIT1 influences class switch recombination. \(2017\) *Proc Natl Acad Sci U S A*. July 19.](#)

2016

[S. Dadi, S. Chhangawala, B.M. Whitlock, R.A. Franklin, C.T. Luo, S.A. Oh, A. Toure, Y. Pritykin, M. Huse, C.S. Leslie, M.O. Li. Cancer Immunoreveillance by Tissue-resident Innate Lymphoid Cells and Innate-like T Cells. *Cell* 2016, 164: 365-377.](#)

